Emerging treatments
Your Organisational Guidance
ebpracticenet urges you to prioritise the following organisational guidance:
Multimodale aanpak van chronische primaire pijn (CPP) in de eerstelijnszorgPublished by: Werkgroep Ontwikkeling Richtlijnen Eerste Lijn (Worel)Last published: 2024Prise en charge multimodale de la douleur chronique primaire (DCP) en première ligne de soinsPublished by: Groupe de Travail Développement de recommmandations de première ligneLast published: 2024Vitamin D
Patients with chronic pain may have higher risk of vitamin D deficiency; therefore, measurement of vitamin D levels and replacement should be considered if deficient.[99][100]
Cannabis-based medicines
There is some evidence that cannabis-based medicines may reduce chronic pain, including neuropathic pain, in some patients.[101][102] BMJ: medical cannabis or cannabinoids for chronic pain: a clinical practice guideline Opens in new window The American College of Physicians (ACP) recommends that if patients are considering using cannabis-based drugs to manage chronic non-cancer pain, clinicians should engage in discussions about their benefits and risks. It advises that the harms of cannabis-based drugs are likely to outweigh the benefits for young adults and adolescents, patients with current or past substance use disorder, patients with serious mental illness, frail patients, and patients at risk of falling; that these drugs should be avoided in patients who are pregnant, breastfeeding, or trying to conceive; and that inhaled cannabis should not be used to manage chronic non-cancer pain.[103] Further research is required into the benefits and harms of these medicines for patients with chronic pain conditions.
Use of this content is subject to our disclaimer